GLP-1 Therapy, Done Medically
Semaglutide and tirzepatide have changed the medical management of obesity and metabolic disease. They reduce appetite signaling, slow gastric emptying, and improve insulin sensitivity. At Atlas & Willow in Clarksville, Tennessee, these medications are prescribed inside a program — not as a standalone refill — with labs, body composition tracking, and structured follow-up.
Our patients receive a thorough evaluation, transparent pricing, and a clinician who knows their case. We are equally direct about who is not a candidate: patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, active pancreatitis, or other contraindications are not appropriate for therapy.
How We Compare Semaglutide and Tirzepatide
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GLP-1 and GIP receptors and tends to produce greater average weight loss in clinical trials. Choosing between them is a clinical conversation: comorbidities, prior medication response, tolerability, cost, supply, and patient goals all matter.
We discuss the trade-offs in plain language, prescribe at the appropriate starting dose, and titrate based on tolerance and response. Lab monitoring is aligned to the medication and to any conditions present.
Why Hormones Belong in the Conversation
GLP-1 medications are powerful, but they are not a substitute for addressing the rest of the metabolic picture. Hypothyroidism, insulin resistance, low testosterone, perimenopause and menopause, sleep apnea, and cortisol dysregulation all influence weight and the durability of weight loss.
Atlas & Willow integrates hormone evaluation into every weight consultation when relevant. Our patients receive medical weight loss care that respects how complex weight actually is.